OncoMatch/Clinical Trials/NCT05303467
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Is NCT05303467 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies TheraSphere GBM for glioblastoma multiforme.
Treatment: TheraSphere GBM — The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Performance status
WHO 0–2
Prior therapy
Must have received: surgery
Prior surgery
Must have received: radiation therapy
treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)
Must have received: chemotherapy
treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)
Cannot have received: cranial radiotherapy
Exception: no more than 1 course of prior cranial radiotherapy (EBRT)
Have received more than 1 course of prior cranial radiotherapy (EBRT)
Cannot have received: radiosurgery
Have received radiosurgery
Cannot have received: brachytherapy
Have received...brachytherapy
Cannot have received: hypofractionated radiotherapy
Have received...hypofractionated radiotherapy
Cannot have received: systemic therapy
Exception: no more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide
Have received more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide
Cannot have received: intra-arterial cerebral infusion therapy
Have received prior intra-arterial cerebral infusion therapy
Cannot have received: surgery
Exception: no more than 2 surgical GBM-related procedures
Have received more than 2 surgical GBM-related procedures
Cannot have received: thoracic radiation therapy
Have received prior thoracic radiation therapy
Lab requirements
Blood counts
platelets ≥ 100,000/l; absolute neutrophil count ≥1.5 x 10^9/l; hemoglobin ≥9.0 g/dl
Kidney function
creatinine ≤1.5 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- University of California San Diego · San Diego, California
- University of California San Francisco · San Francisco, California
- Mayo Jacksonville · Jacksonville, Florida
- Northwestern Univerity · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05303467 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cranial radiotherapy, radiosurgery, brachytherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages